H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Voyager Therapeutics Inc (VYGR) today and set a price target of $22. The company’s shares closed on Friday at $22.51, close to its 52-week high of $24.24.
Chattopadhyay said:
“With the stock above our $22 price target, we await progress from its other pipeline initiatives including potential IND clearance to make adjustments to our model.”
According to TipRanks.com, Chattopadhyay is a 2-star analyst with an average return of 0.5% and a 45.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Autolus Therapeutics Plc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Voyager Therapeutics Inc is a Strong Buy with an average price target of $24.67.
See today’s analyst top recommended stocks >>
Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.53 million. In comparison, last year the company had a GAAP net loss of $19.93 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VYGR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
